Structure via PubChem · Public domain (PubChem)
اریبولین
Sign in to saveAlso known as 2-(3-Amino-2-hydroxypropyl)hexacosahydro-3-methoxy- 26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy- 7,9-ethano-12,15-methano-9H,15H-furo(3,2-i)furo(2',3'-5,6) pyrano(4,3-b)(1,4)dioxacyclopentacosin-5-(4H)-one, eribulin mesylate, L01XX41, ER-086526, E7389
Eribulin, sold under the brand name Halaven among others, is an anti-cancer medication used to treat breast cancer and liposarcoma.
Key facts
- Drug.Verifiedfields
- changed
- Drug.verifiedrevid
- 461094948
- Drug.image
- Eribulin.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 300
- Drug.USAN
- eribulin mesylate
- Drug.JAN
- eribulin mesilate
- Drug.tradename
- Halaven, Mevlyq
- Drug.MedlinePlus
- a611007
- Drug.DailyMedID
- Eribulin
- Drug.pregnancy_AU
- D
- Drug.routes_of_administration
- Intravenous
- Drug.class
- Antineoplastic
- Drug.ATC_prefix
- L01
- Drug.ATC_suffix
- XX41
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_UK
- POM
via Wikipedia infobox
Chemical data
- Formula
- C40H59NO11
- Molecular weight
- 729.9 g/mol
- IUPAC name
- (1S,3S,6S,9S,12S,14R,16R,18S,20R,21R,22S,26R,29S,31R,32S,33R,35R,36S)-20-[(2S)-3-amino-2-hydroxypropyl]-21-methoxy-14-methyl-8,15-dimethylidene-2,19,30,34,37,39,40,41-octaoxanonacyclo[24.9.2.13,32.13,33.16,9.112,16.018,22.029,36.031,35]hentetracontan-24-one
- SMILES
- C[C@@H]1C[C@@H]2CC[C@H]3C(=C)C[C@@H](O3)CC[C@]45C[C@@H]6[C@H](O4)[C@H]7[C@@H](O6)[C@@H](O5)[C@@H]8[C@@H](O7)CC[C@@H](O8)CC(=O)C[C@H]9[C@H](C[C@H](C1=C)O2)O[C@@H]([C@@H]9OC)C[C@@H](CN)O
- InChIKey
- UFNVPOGXISZXJD-JBQZKEIOSA-N
- XLogP
- 1.1
- Polar surface area
- 146 Ų
- H-bond donors
- 2
- H-bond acceptors
- 12
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2010
- Admin. routes
- parenteral
- Indications
- neoplasm, breast carcinoma, non-small cell lung carcinoma, angiosarcoma
via ChEMBL · EBI
Research
1,184 papers- Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.Lancet (London, England) · 2016
- Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.Lancet (London, England) · 2011
- Eribulin.Drugs · 2011
- Eribulin in advanced liposarcoma and leiomyosarcoma.Expert review of anticancer therapy · 2017
- Clinical and preclinical features of eribulin-related peripheral neuropathy.Experimental neurology · 2022
via PubMed
Wikidata facts
- Mass
- 729.409
- Has use
- medication
Show 7 more facts
- chemical formula
- C₄₀H₅₉NO₁₁
- isomeric SMILES
- C[C@@H]1C[C@@H]2CC[C@H]3C(=C)C[C@@H](O3)CC[C@]45C[C@@H]6[C@H](O4)[C@H]7[C@@H](O6)[C@@H](O5)[C@@H]8[C@@H](O7)CC[C@@H](O8)CC(=O)C[C@H]9[C@H](C[C@H](C1=C)O2)O[C@@H]([C@@H]9OC)C[C@@H](CN)O
- canonical SMILES
- CC1CC2CCC3C(=C)CC(O3)CCC45CC6C(O4)C7C(O6)C(O5)C8C(O7)CCC(O8)CC(=O)CC9C(CC(C1=C)O2)OC(C9OC)CC(CN)O
- medical condition treated
- breast cancer
- stylized name
- eriBULin
- significant drug interaction
- anagrelide
- Commons category
- Eribulin
Sources (7)
via Wikidata · CC0